Literature DB >> 186092

Abnormal fibrin polymerization in liver disease.

G Green, J M Thomson, I W Dymock, L Poller.   

Abstract

Although there have been isolated reports of an acquired abnormal fibrinogen in patients with liver disease, its frequency and clinical significance is not known. In this study 121 consecutive patients with a wide spectrum of hepatic disorders were screened for abnormal fibrin polymerization. A simple colorimetric method using Reptilase was employed. Of 32 patients with proven cirrhosis, 16 (50%) showed abnormal fibrin polymerization. The incidence in decompensated alcoholic cirrhosis was particularly high. The abnormality was also detected in all patients with acute liver failure and seven of 15 with chronic active liver disease. Clinical improvement often correlated with its disappearance. Two patients with primary liver cell tumours demonstrated the abnormal polymerization. In patients with bleeding oesophageal varices the detection of abnormal fibrin polymerization was associated with a poor prognosis. None of the patients with surgical obstructive jaundice (26) or miscellaneous liver disorders (37) had abnormal fibrin polymerization. The occurrence of abnormal fibrin polymerization in liver disease is more frequent than previously suspected and usually signifies severe primary hepatocellular dysfunction. Evidence is presented to support the presence of a primary abnormality of fibrinogen as the cause of impaired fibrin monomer polymerization.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 186092     DOI: 10.1111/j.1365-2141.1976.tb03589.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Haemostatic problems in liver disease.

Authors:  D A Kelly; E G Tuddenham
Journal:  Gut       Date:  1986-03       Impact factor: 23.059

2.  Acquired dysfibrinogenaemia masquerading as disseminated intravascular coagulation in acute pancreatitis.

Authors:  J T Wilde; W E Thomas; D A Lane; M Greaves; F E Preston
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

3.  Sensitive and rapid measurement of fibrin polymerisation by laser nephelometry.

Authors:  A Ruiz-Arguelles; B Perez-Romano
Journal:  J Clin Pathol       Date:  1986-02       Impact factor: 3.411

4.  Coagulation defect of congenital tyrosinaemia.

Authors:  D I Evans; I B Sardharwalla
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

5.  Dysfibrinogenaemia and liver cell growth.

Authors:  R D Barr; M Allardyce; P W Brunt; J L McPhie
Journal:  J Clin Pathol       Date:  1978-01       Impact factor: 3.411

6.  Association of abnormal fibrin polymerisation with severe liver disease.

Authors:  G Green; L Poller; J M Thomson; I W Dymock
Journal:  Gut       Date:  1977-11       Impact factor: 23.059

7.  Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease.

Authors:  J Martinez; J E Palascak; D Kwasniak
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

8.  Prothrombin time derived fibrinogen determination on Sysmex CA-6000.

Authors:  A S Lawrie; S J McDonald; G Purdy; I J Mackie; S J Machin
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

9.  Thromboelastographic reference ranges for a cirrhotic patient population undergoing liver transplantation.

Authors:  Lesley De Pietri; Marcello Bianchini; Gianluca Rompianesi; Elisabetta Bertellini; Bruno Begliomini
Journal:  World J Transplant       Date:  2016-09-24

Review 10.  The contact system in liver injury.

Authors:  Chandini Rangaswamy; Reiner K Mailer; Hanna Englert; Sandra Konrath; Thomas Renné
Journal:  Semin Immunopathol       Date:  2021-06-14       Impact factor: 9.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.